Jackson Grant Investment Advisers Inc. Sells 648 Shares of Pfizer Inc. (NYSE:PFE)

Jackson Grant Investment Advisers Inc. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 6.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,824 shares of the biopharmaceutical company’s stock after selling 648 shares during the period. Jackson Grant Investment Advisers Inc.’s holdings in Pfizer were worth $261,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Czech National Bank grew its position in Pfizer by 6.9% in the third quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock valued at $33,407,000 after acquiring an additional 74,737 shares during the period. Atomi Financial Group Inc. increased its position in shares of Pfizer by 12.1% during the 3rd quarter. Atomi Financial Group Inc. now owns 42,433 shares of the biopharmaceutical company’s stock worth $1,228,000 after purchasing an additional 4,583 shares in the last quarter. Country Trust Bank lifted its holdings in Pfizer by 46.9% during the 3rd quarter. Country Trust Bank now owns 4,700 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 1,500 shares during the last quarter. Artemis Investment Management LLP boosted its position in Pfizer by 27.9% in the third quarter. Artemis Investment Management LLP now owns 460,127 shares of the biopharmaceutical company’s stock valued at $13,316,000 after buying an additional 100,492 shares in the last quarter. Finally, O Keefe Stevens Advisory Inc. grew its stake in Pfizer by 24.0% during the third quarter. O Keefe Stevens Advisory Inc. now owns 64,868 shares of the biopharmaceutical company’s stock worth $1,877,000 after buying an additional 12,567 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE stock opened at $26.46 on Thursday. The firm’s 50 day moving average price is $26.27 and its two-hundred day moving average price is $27.79. The stock has a market cap of $149.94 billion, a PE ratio of 35.76, a PEG ratio of 0.66 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the firm earned $0.10 earnings per share. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.50%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 232.44%.

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. Citigroup reduced their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Wolfe Research began coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.